Trial Profile
Dose-Reduced [busulfan + fludarabine] Versus Standard Conditioning [busulfan + cyclophosphamide] Followed by Allogeneic Stem Cell Transplantation in Patients With MDS [myelodysplastic syndromes] or sAML [secondary acute myeloid leukaemia]: A Randomised Phase III Study (RICMAC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Busulfan; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms RICMAC
- 04 Dec 2018 Long-term follow up results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 02 May 2017 Results published in the Journal of Clinical Oncology
- 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.